Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 Sep 23:7:2050313X19878047.
doi: 10.1177/2050313X19878047. eCollection 2019.

Treatment of pulmonary thromboembolism with edoxaban in a cancer patient with borderline fulfillment of the dose reduction criteria

Takuro Takama  1 , Mitsunori Fukue  1 , Koji Kanaya  2 , Masato Taniuchi  1
Affiliations
Case Reports

Treatment of pulmonary thromboembolism with edoxaban in a cancer patient with borderline fulfillment of the dose reduction criteria

Takuro Takama et al. SAGE Open Med Case Rep. .

Abstract

Venous thromboembolism is the most common cause of death in cancer patients with venous thrombosis. Treatment of venous thrombosis is important in cancer patients, as it can have a major impact on prognosis. We report a case of advanced gastric cancer that was discovered owing to pulmonary thromboembolism and describe the treatment for both conditions. Dose reduction criteria of edoxaban are established. Appropriate dose was based on body weight and creatinine clearance; patients with creatinine clearance values slightly exceeding or below 50 are considered to be on the borderline of the dose reduction criteria. This case had borderline value (body weight: 63 kg, creatinine clearance: 46 mL/min). We observed no response after initiating treatment with 30 mg edoxaban; however, pulmonary thrombus disappeared after increasing the dose to 60 mg edoxaban. When selecting an anticoagulation drug in borderline patients with cancer-associated thrombosis, dose increase should be considered if hemorrhage risk is assessed.

Keywords: Pulmonary thromboembolism; cancer patient; direct oral anticoagulants; edoxaban.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
(a) and (b) Contrast-enhanced CT revealing submassive thrombus in both pulmonary arteries (arrows); (c)–(e) contrast-enhanced CT revealing complete disappearance of the thrombus over a period of 3 months (arrows).
Figure 2.
Figure 2.
The entire circumference of the wall thickening at antrum to pyloric region of stomach (arrows).
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Blom JW, Doggen CJ, Osanto S, et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293: 715–722. - PubMed
    1. Varki A. Trousseau’s syndrome: multiple definitions and multiple mechanisms. Blood 2007; 110: 1723–1729. - PMC - PubMed
    1. Khorana AA, Francis CW, Culakova E, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5(3): 632–634. - PubMed
    1. Khorana AA. Venous thromboembolism and prognosis in cancer. Thromb Res 2010; 125: 490–493. - PMC - PubMed
    1. Sørensen HT, Mellemkjaer L, Olsen JH, et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343(25): 1846–1850. - PubMed

Publication types

LinkOut - more resources